![4-(2-((4-(2-(PYRIDIN-2-YL)-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOL-3-YL)QUINOLIN-7-YL)OXY)ETHYL)MORPHOLINE structure, CAS 700874-71-1](/structures/150000/134262_1_700874_71_1.png)
CAS Number700874-71-1
Synonyms7-(2-morpholin-4-yl-ethoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinoline; cc-120; 7-[2-(morpholin-4-yl)ethoxy]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline; 7-[2-(4-Morpholinyl)ethoxy]-4-[2-(2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline; Dihydropyrrolopyrazole,15d
Molecular FormulaC26H27N5O2
Molecular Weight441.52
Purity≥98 (HPLC)%
Density1.3±0.1 g/cm3
Boiling Point640.9±55.0 °C at 760 mmHg
Appearancepowder
EINECS0
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 700874-71-1 |
| Catalog No. | 2A-0134262 |
| Chinese Name | 4-[5,6-二氢-2-(2-吡啶)-4H-吡咯并[1,2-b]吡唑-3-基]-7-[2-(4-吗啉)乙氧基]喹啉 |
| Synonyms | 7-(2-morpholin-4-yl-ethoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinoline; cc-120; 7-[2-(morpholin-4-yl)ethoxy]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline; 7-[2-(4-Morpholinyl)ethoxy]-4-[2-(2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline; Dihydropyrrolopyrazole,15d |
| Molecular Formula | C26H27N5O2 |
| Molecular Weight | 441.52 |
| Purity | ≥98 (HPLC) |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 640.9±55.0 °C at 760 mmHg |
| Appearance | powder |
| Storage Condition | -20°C |
| Application | LY2109761 is an orally available, selective TGF-β receptor type I/II inhibitor with Ki of 38 nM and 300 nM respectively. |
| EINECS | 0 |
| HTC | 2934999090 |
| UN(IATA) | 0 |
| MDL Number | MFCD12923354 |
| SMILES | [n]21nc(c(c2CCC1)c4c5c(ncc4)cc(cc5)OCCN6CCOCC6)c3ncccc3 |
| InChI | 1S/C26H27N5O2/c1-2-9-27-22(4-1)26-25(24-5-3-11-31(24)29-26)21-8-10-28-23-18-19(6-7-20(21)23)33-17-14-30-12-15-32-16-13-30/h1-2,4,6-10,18H,3,5,11-17H2 |
| InChI Key | IHLVSLOZUHKNMQ-UHFFFAOYSA-N |
| NACRES Code | NA.21 |
| UNSPSC | 12352200 |
| MSDS | msds/134262_1_700874_71_1.pdf |
| Use of | LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with Kis of 38 nM and 300 nM, respectively. Properties Name 4-[2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxyethyl]morpholine Synonym More Synonyms LY2109761 Biological Activity Description LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with Kis of 38 nM and 300 nM, respectively. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> TGF-beta/Smad >> TGF-β Receptor Research Areas >> Cancer Ki: 38 nM (TβRI), 300 nM (TβRII) References [1]. Melisi D, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther, 2008, 7(4), 829-840. [2]. Fransvea E, et al. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology, 2008, 47(5), 1557-1566. [3]. Zhang M, et al. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res, 2011, 71(23), 7155-7167. Chemical & Physical Properties Molecular Formula C26H27N5O2 Exact Mass 441.216461 PSA 65.30000 Index of Refraction 1.700 Safety Information HS Code 2934999090 Synthetic Route Total: 1 Page morpholine CAS#:110-91-8 methanesulfonic... CAS#:700874-75-5 CAS#:700874-71-1 Precursor & DownStream Precursor 2 CAS#:110-91-8 morpholine CAS#:700874-75-5 methanesulfonic... DownStream 0 |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in Heterocyclic Building Blocks | ||
|---|---|---|
| 4-(2,2,4-TRIMETHYLCHROMAN-4-YL)PHENOL | 472-41-3 | 2A-1134190 |
| 4-(2,3-DICHLORO-PHENYL)-2,6-DIMETHYL-1,4-DIHYDRO-PYRIDINE-3,5-DICARBOXYLIC ACID 3-(2-CYANO-ETHYL) ESTER 5-METHYL ESTER | 110962-94-2 | 2A-2134195 |
| 4-(2,3-DICHLOROPHENYL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID | 138279-32-0 | 2A-0134196 |
| 4-(2,6-DICHLOROPYRIMIDIN-4-YL)MORPHOLINE | 52127-83-0 | 2A-0134239 |
| 4-(2,7-DICHLOROPYRIDO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE | 938443-21-1 | 2A-0134242 |
| 4-(2-(2,6-DICHLOROPHENOXY)ETHYL)MORPHOLINE | 372183-73-8 | 2A-0134296 |
| 4-(2-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENOXY)ETHYL)MORPHOLINE | 756520-70-4 | 2A-0134353 |
| 4-(2-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENOXY)ETHYL)MORPHOLINE | 690636-28-3 | 2A-0134368 |
| 4-(2-(4-CHLOROPYRIDIN-2-YL)-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOL-3-YL)QUINOLINE | 476475-18-0 | 2A-0134402 |
| 4-(2-(6-BROMOPYRIDIN-2-YL)-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOL-3-YL)QUINOLINE | 476475-03-3 | 2A-0134415 |
| Browse all Heterocyclic Building Blocks products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA